GAITHERSBURG, Md., June 15, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the publication of a citywide evaluation of Washington, D.C.’s healthcare facilities to gauge the prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) throughout the District of Columbia. OpGen’s Acuitas DNA tests and Acuitas Lighthouse® bioinformatics were utilized to test over 1,000 patient samples across 16 institutions, including eight acute care hospitals, two long-term acute care hospitals, one inpatient rehabilitation facility, and five skilled nursing facilities.

The results, published in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), revealed the prevalence of CRE, a family of highly pathogenic antibiotic-resistant organisms, are endemic across Washington, D.C. healthcare facilities, with 5.2% of inpatients testing positive for the bacteria. As a result of this study, healthcare facilities were able to establish a baseline prevalence of CRE in Washington, D.C., and demonstrate the ability to work together to identify and prevent future outbreaks of dangerous antibiotic-resistant organisms.

“This collaborative effort to understand the prevalence of a CRE across multiple institutions has helped create awareness of the problem of MDROs in our healthcare facilities,” said Evan Jones, Chairman and CEO of OpGen. “Our technology proved to be valuable in both understanding the epidemiology of CRE and demonstrated that early detection of threats may provide timely information enabling clinicians to take the necessary precautions to protect patients and co-workers.”

About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.

OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.

Forward-Looking Statements
This press release includes statements relating to the company's products and services development efforts.  These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek regulatory approval for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com

Investor and Media Contact:
Cammy DuongMacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com